pramipexole (Mirapex, Mirapex ER)

  • Pharmacy Author:
    Omudhome Ogbru, PharmD

    Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.

  • Medical and Pharmacy Editor: Jay W. Marks, MD
    Jay W. Marks, MD

    Jay W. Marks, MD

    Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.

What else should I know about Mirapex?

What preparations of Mirapex are available?
How should I keep Mirapex stored?

Immediate release tablets: 0.125, 0.25, 0.5, 0.75, 1, and 1.5 mg; extended release 24 hour tablets: 0.375, 0.75, 1.5, 2.25, 3, 3.75, and 4.5 mg

Tablets should be stored at room temperature, between 15 C to 30 C (59 F to 86 F). Tablets should be protected from light and kept out of the reach of children.

How does Mirapex work?

Pramipexole stimulates dopamine receptors in the brain. The exact mechanism of action of pramipexole in Parkinson's disease is unknown. However, treatment benefits are thought to be related to the stimulation of dopamine receptors in the area of the brain known as the striatum. Pramipexole may improve movement performance and activities of daily living in patients usually within 2-3 weeks of starting treatment. The exact mechanism of action of pramipexole for the treatment of RLS is unknown. Benefits of treatment are thought to be associated with stimulating dopamine receptors in the brain.

When was Mirapex approved by the FDA?
  • The US FDA approved pramipexole for the treatment of Parkinson's disease in July, 1997.
  • Extended release pramipexole (Mirapex ER) was approved by the FDA for the treatment of early Parkinson's disease in February, 2010.
  • In March 2010, the FDA extended the approval of the extended release formulation to the treatment of advanced, idiopathic Parkinson's disease.
  • Immediate release pramipexole was approved by the FDA for the treatment of moderate to severe primary RLS in November, 2006.

REFERENCE: FDA Prescribing Information.

Medically Reviewed by a Doctor on 11/3/2016

Quick GuideRLS Remedies in Pictures: Home Care for Better Sleep

RLS Remedies in Pictures: Home Care for Better Sleep
FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

RxList Logo

Need help identifying pills and medications?

Use the pill identifier tool on RxList.

Subscribe to MedicineNet's Newsletters

Get the latest health and medical information delivered direct to your inbox!

By clicking Submit, I agree to the MedicineNet's Terms & Conditions & Privacy Policy and understand that I may opt out of MedicineNet's subscriptions at any time.

Health Solutions From Our Sponsors